Bempedoic acid is a prodrug that is activated in the liver, so it is inactive in muscle tissue and appears to carry a lower risk of myopathy versus statins.
Adding to the challenge is the current lack of widespread screening programs for early stage T1DM in the general population, making it difficult to identify all patients who may benefit from teplizumab.
